# US 2021/0079043 A1 · Modulation of structured polypeptide specificity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079043 A1
- Document ID: US20210079043A1
- Status: Published application
- Kind: A1
- Application number: 16/987,764
- Filed: 2020-08-07
- Published: 2021-03-18
- Earliest claimed: 2013-04-11
- Assignees: BicycleRD Limited
- Applicants: BicycleRD Limited
- Inventors: Daniel Paul Teufel; Catherine STACE; Edward WALKER; John TITE
- Web page: https://patentgrep.com/patent/US20210079043A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/50: Cyclic peptides containing at least one abnormal peptide link
- C07K 7/54: with at least one abnormal peptide link in the ring
- C12N 9/6445: {Kallikreins (3.4.21.34; 3.4.21.35)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention describes peptide ligands specific for human plasma Kallikrein.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A method of preventing, suppressing or treating an inflammatory state, allergic hypersensitivity, cancer, bacterial or viral infection, ophthalmic disorder, autoimmune disorder, and/or impaired retinal vessel permeability in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a peptide ligand specific for human Kallikrein, wherein the peptide comprises a polypeptide comprising three reactive groups, separated by two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that two polypeptide loops are formed on the molecular scaffold, wherein the loops of the peptide ligand comprise five amino acids and wherein the polypeptide comprises the motif Grx1x2x3x4x5Grx6x7x8x9x10Gr, wherein x1 and x9 are independently any amino acid, x2 is tryptophan or phenylalanine, x3 is proline or azetidine carboxylic acid, x4 is alanine or tyrosine, x5 is arginine, N-methyl arginine, homoarginine, or guanidylphenylalanine, x6 is tyrosine, leucine or alanine, x7 is histidine, x8 is glutamine or threonine, x10 is leucine, and Gr represents cysteine; and wherein one or more peptide bonds are replaced by ΨCH2NH.

### Claim 19 (depends on 18)

The method according to claim 18, wherein in the first loop x3 is azetidine carboxylic acid; and/or in the first loop x5 is N-methyl arginine or homoarginine or guanidylphenylalanine.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the polypeptide comprises a first loop which comprises the motif Grx1Fx3Yx5Gr (SEQ ID NO: 6), wherein x3 is azetidine carboxylic acid and/or x5 is N-methyl arginine or homoarginine or guanidylphenylalanine.

### Claim 21 (depends on 18)

The method according to claim 18, wherein the peptide ligand is attached to an antibody or a fragment thereof.

### Claim 22 (depends on 21)

The method according to claim 21, wherein in the first loop x3 is azetidine carboxylic acid; and/or in the first loop x5 is N-methyl arginine or homoarginine or guanidylphenylalanine.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the polypeptide comprises a first loop which comprises the motif Grx1Fx3Yx5Gr (SEQ ID NO: 6), wherein x3 is azetidine carboxylic acid and/or x5 is N-methyl arginine or homoarginine or guanidylphenylalanine.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the peptide ligand comprises: Cys Ser1 Phe 2 Aze3 Tyr4 HArg5 Cys Ala(ΨCH2NH)6 His7 Gln8 Asp9 Leu10 Cys (SEQ ID NO: 201).

### Claim 25 (depends on 21)

The method according to claim 21, wherein the peptide ligand comprises:

### Claim 26 (depends on 21)

The method according to claim 21, wherein the antibody fragment is selected from an antibody light chain constant region (CL), an antibody CH1 heavy chain domain, an antibody CH2 heavy chain domain, an antibody CH3 heavy chain domain, or any combination thereof, in addition to the one or more constant region domains.

### Claim 27 (depends on 21)

The method according to claim 21, wherein the antibody or fragment thereof comprises a hinge region of an antibody.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the hinge region comprises the region between the CH1 and CH2 domains of an IgG molecule.

### Claim 29 (depends on 18)

The method according to claim 18, wherein the antibody or fragment thereof comprises an Fc region of an IgG molecule.

### Claim 30 (depends on 25)

The method according to claim 25, wherein the peptide ligand is attached to an antibody or a fragment thereof, wherein the antibody fragment is selected from an antibody light chain constant region (CL), an antibody CH1 heavy chain domain, an antibody CH2 heavy chain domain, an antibody CH3 heavy chain domain, or any combination thereof, in addition to the one or more constant region domains.

### Claim 31 (depends on 25)

The method according to claim 25, wherein the peptide ligand is attached to an antibody or a fragment thereof, which comprises a hinge region of an antibody.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the hinge region comprises the region between the CH1 and CH2 domains of an IgG molecule.

### Claim 33 (depends on 25)

The method according to claim 25, wherein the peptide ligand is attached to an antibody or a fragment thereof, which comprises an Fc region of an IgG molecule.

### Claim 34 (depends on 18)

The method according to claim 18, wherein the molecular scaffold is a tris(bromomethyl)benzene, or a derivative thereof.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the molecular scaffold is 1,3,5-tris(bromomethyl)-2,4,6-trimethylbenzene, 1,3,5-tris(bromomethyl)benzene, or 1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene.

### Claim 36 (depends on 34)

The method according to claim 34, wherein the molecular scaffold is 1,3,5-tris(bromomethyl)benzene.

### Claim 37 (depends on 18)

The method according to claim 18, wherein the ophthalmic disorder is age related macular degeneration (ARMD), exudative macular degeneration, macular oedema, aged disciform macular degeneration, cystoid macular oedema, palpebral oedema, retinal oedema, diabetic retinopathy, acute macular neuroretinopathy, central serous chorioretinopathy, chorioretinopathy, choroidal neovascularization, neovascular maculopathy, neovascular glaucoma, obstructive arterial and venous retinopathies (e.g. retinal venous occlusion or retinal arterial occlusion), central retinal vein occlusion, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, macular oedema occuring as a result of aetiologies such as disease (e.g. diabetic macular oedema), eye injury or eye surgery; retinal ischemia or degeneration produced for example by injury, trauma or tumours, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, thygeson keratitis, progressive mooren's ulcer, an ocular inflammatory disease caused by bacterial or viral infection, and by an ophthalmic operation, an ocular inflammatory disease caused by a physical injury to the eye, a symptom caused by an ocular inflammatory disease including itching, flare, oedema and ulcer, erythema, erythema exsudativum multiforme, erythema nodosum, erythema annulare, scleroedema, dermatitis, angioneurotic oedema, laryngeal oedema, glottic oedema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.
